MCM
HAE icon

MAI Capital Management’s Haemonetics HAE Stock Holding History

MAI Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-61
Closed -$3.44K – 3191
2026
Q1 		$3.44K Sell
61
-11
-15% -$716 ﹤0.01% 3698
2025
Q4 		$5.77K Buy
+72
New +$4.84K ﹤0.01% 3066
2025
Q1 		– Sell
-52
Closed -$4.06K – 3497
2024
Q4 		$4.06K Buy
+52
New +$4.18K ﹤0.01% 2840

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's HAE Position: Q2 2026 in Review

MAI Capital Management sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 61 shares — an estimated $3.44K sold.

MAI Capital Management first reported a position in HAE in Q4 2024 and held it in 3 quarters. The position peaked at $5.77K in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • MAI Capital Management reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 61 Haemonetics shares in Q2 2026, an estimated $3.44K.
  • MAI Capital Management first reported a position in Haemonetics in Q4 2024 and held it in 3 quarters.
  • MAI Capital Management's Haemonetics position peaked at $5.77K in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.